{"name":"Equilibre Biopharmaceuticals B.V.","slug":"equilibre-biopharmaceuticals-b-v","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxQSU1nZ0VqM3RfRGppZVpmaW9IaWEtSXFzMDVLc3QybFZPQnMyb2szcm0xeDB2UGNJeVQ1dUpEMlU4Sy0tamtsQ0lJV0Z4VGc4WFdkcjJTN0VJa1RhRXB6YWNNempmZURoRE95Y05ocktOeEFOeHdtcHkwT3d5NnYwTmNDNjNDVUFERkRNTk9BOVp6cU1SSmk0YUNKQQ?oc=5","date":"2026-03-24","type":"trial","source":"openPR.com","summary":"Epilepsy Clinical Trial Pipeline Appears Robust With 75+ Key - openPR.com","headline":"Epilepsy Clinical Trial Pipeline Appears Robust With 75+ Key","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowJBVV95cUxNelhGRWdNOUpyWkFNSHZzMml5MHFvYnpHMmVhN0RjRmZ6UW5WR0hMeTM2SG91enFaNUk0ODRmekxuQWxjMHo1eHRpRlR4ZXZLNFpIOEkzQTRMMnNDaWNiUXQtMFFON2VFSWRJUUp4MXUySklNUThyRXlVSlYyOEVyR1hENnBUT1gtQmtGTDE1clFDNmhYWWNGTG1VSVFWUXl1cnBSNW9Rdkdpa0FFU3RsWlZXVVVJc2VoOFZRZ1lPekVyTUtLZGNGM0cxMlZaQkstMFRzbkx5YVNHdzJmbm1qOEdKWFhQQ3dDNWFCZXJYS2JOUjhCM0Z2OVV0Z3NocUpVRTJSY3BKSzVoaVowOWpkZzROSXV3dkFVRm9EVVlxNmNPVmM?oc=5","date":"2025-04-08","type":"pipeline","source":"globenewswire.com","summary":"Developmental and Epileptic Encephalopathies Market to - globenewswire.com","headline":"Developmental and Epileptic Encephalopathies Market to","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2023-01-30","type":"trial","source":"PR Newswire","summary":"Equilibre Biopharmaceuticals Announces Positive Topline Results from Phase 2 Clinical Trial of EQU-001 (NCT05063877) for Safety, Tolerability and Preliminary Efficacy as Adjunctive Therapy for Focal S","headline":"Equilibre Biopharmaceuticals Announces Positive Topline Results from Phase 2 Clinical Trial of EQU-001 (NCT05063877) for","sentiment":"positive"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}